CRISPR Therapeutics AG CRSP
51.78 USD +1.78 (+3.57%)
At closeNov 4, 2026, 6:13 PM EST
51.23 -0.55 -1.05%
After hours · Nov 4, 6:13 PM ET
50.19 Day range 52.50
44.12 52-week range 63.45
- YTD
- -1.27%
- 1 year
- -8.22%
Analyst view
Consensus: buy
Buy
Price target (mean) 74.33 +43.6% upside
Now 51.78
- Target (low)
- 44.00
- Target (mean)
- 74.33
- Target (high)
- 110.00
Ratings (0m) 23 13 buy · 10 hold · 0 sell
- Strong buy4
- Buy9
- Hold10
- Sell0
- Strong sell0
Recommendation trend
- This month 23
- 1 month ago 22
- 2 months ago 22
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.06 | -1.50 – -0.46 | -1.17 | +9.4% | 17.43M | +1917.2% | 17 |
| Next quarter | -1.09 | -1.33 – -0.73 | -1.37 | +20.1% | 19.52M | +1239.1% | 17 |
| Current year | -4.52 | -4.99 – -4.12 | -6.47 | +30.2% | 41.81M | +1091.3% | 16 |
| Next year | -3.58 | -5.36 – -0.42 | -4.52 | +20.6% | 132.47M | +216.8% | 17 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Nov 3, 2026 | Needham | Reiterated | Buy | Buy |
| Oct 15, 2026 | UBS | Initiated | — | Neutral |
| Aug 31, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Aug 31, 2026 | Needham | Reiterated | Buy | Buy |
| Aug 25, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Aug 4, 2026 | Citigroup | Maintained | Buy | Buy |
| Jul 8, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 6, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| May 13, 2026 | Bernstein | Maintained | Market Perform | Market Perform |
| May 6, 2026 | Citigroup | Maintained | Buy | Buy |
| Mar 17, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Feb 17, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Feb 13, 2026 | TD Cowen | Maintained | Hold | Hold |
| Feb 13, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Feb 13, 2026 | Needham | Maintained | Buy | Buy |
| Jan 30, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Dec 23, 2025 | Needham | Reiterated | Buy | Buy |
| Dec 23, 2025 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Nov 26, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Nov 12, 2025 | Citigroup | Maintained | Buy | Buy |
| Nov 11, 2025 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Nov 11, 2025 | Baird | Maintained | Neutral | Neutral |
| Nov 10, 2025 | Needham | Maintained | Buy | Buy |
| Oct 17, 2025 | B of A Securities | Maintained | Buy | Buy |
| Oct 10, 2025 | Needham | Reiterated | Buy | Buy |
| Sep 23, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 18, 2025 | JP Morgan | Initiated | — | Overweight |
| Aug 7, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 6, 2025 | Barclays | Maintained | Equal-Weight | Equal-Weight |